Jared Whitlock


Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

Neurocrine’s Tourette Syndrome Drug Misses Primary Goal

San Diego-based Neurocrine’s drug for Tourette syndrome failed to meet its primary goal in a mid-stage clinical trial, the company reported Dec. 12.

Following the Local Biotech VC Funding Trail

The San Diego Business Journal frequently chronicles local funding rounds and the big dreams that accompany them. But what about the largest venture capital sources locally?

Tease photo

House Bill Would Further Delay Medical Device Tax

Recently proposed legislation would further push back a 2.3 percent excise tax on medical device makers, San Diego’s ResMed, NuVasive and Ra Medical Systems among them.

Healthcare District Dumps At-Large Elections

HEALTH: Grossmont Makes Move; Palomar Considers Election Change

Under the threat of a lawsuit from a Malibu attorney, one San Diego hospital district is moving to a new type of election system, while another will consider doing so.

Tease photo

Pfizer Move to Transfer 100 Jobs to San Diego

Pharmaceutical behemoth Pfizer is set to close a South San Francisco site and relocate 100 jobs to its research and development campus in La Jolla.

Tease photo

Report: Human Longevity’s Valuation Falls 80%

Human Longevity Inc.’s latest valuation: $310 million, down more than 80 percent from early 2017, according to the Wall Street Journal.

Oxeia Leading the Pack on Potential Concussion Treatments

Oxeia Leading the Pack on Potential Concussion Treatments

Tease photo

Concentration Of Precision Health Companies

Precision health factors in a person’s genes, medical history, environment and more for diagnosis and treatment.

Tease photo

LunaDNA Launches Platform Giving Shares for DNA Data

LunaDNA’s first-of-its-kind platform giving shares for contributing DNA data got approval earlier this week from the U.S. Securities and Exchange Commission.

Ionis’ ALS Drug Candidate Nets $35M Payment from Biogen

Biogen exercised a licensing option and will pay Carlsbad’s Ionis Pharmaceuticals $35 million for a drug candidate aimed at amyotrophic lateral sclerosis, or ALS.

ViaCyte Gets $80M Series D For Pursuit of Diabetes Cure

ViaCyte recently hauled in an $80 million Series D round to advance therapies that the company called a potential “functional cure” for Type 1 diabetes patients.

Tease photo

Viracta Plots Entry Into China with $10M Financing and Partnership

San Diego-based Viracta Therapeutics intends to bring a cancer therapy candidate to China through a recently inked partnership with Chinese drug company Salubris

Court Narrows Use of Non-Solicitation Clause

LEGAL: AMN Loses Bid to Limit Ex-Recruiters’ Actions

A recent ruling involving competing health care staffing firms headquartered in San Diego makes it tougher for employers to restrict past employees from soliciting former clients.

Tease photo

Neurelis Buys Aegis Therapeutics

Neurelis has acquired Aegis Therapeutics, bringing together two San Diego companies.

In Another Acquisition, ResMed Buys Propeller Health for $225M

ResMed will plunk down $225 million to acquire Propeller Health, marking the San Diego company’s third acquisition announcement this year.

Dexcom to Pay $250M in Stock Through Amended Deal With Verily

San Diego’s Dexcom will pay $250 million in stock to Verily — a subsidiary of Google parent company Alphabet — as part of an amended deal. One analyst called the revision a financial and strategic win for Dexcom.

Tease photo

Manageable Technology Makes Aging in Place More Possible

HEALTH: Software Is Personalized, Even Capable Of Some Conversation

More than 87 percent of people 65 years or older want to stay in their current home as they age, according to a 2014 AARP survey. Among them: Dan Deninger and his wife, Cindy.

Tease photo

Local Cos. Blend Tech and Health Care to Give Seniors Tools to Cope

Dan Deninger — an Oceanside senior unversed in computers or smartphones — dictates messages to his assistant, Lisa. She also chimes in with medication reminders, historical facts and what’s coming up on the calendar.

Tease photo

New CEO Named at Sharp Healthcare

Sharp Healthcare has found a CEO to succeed Mike Murphy, who announced his retirement in April.

ViaCyte Gets $80M Series D for Diabetes Work

ViaCyte recently hauled in an $80 million Series D round to advance therapies that the company called a potential “functional cure” for Type 1 diabetes patients.

Mesa Biotech Test Obtains FDA Clearance

A respiratory test from San Diego-based Mesa Biotech recently received U.S. Food and Drug Administration clearance and a key waiver.

Jecure Therapeutics Acquired

San Diego-based Jecure Therapeutics and its inflammatory disease platform has been snapped up by Genentech, it was announced Nov. 27.

Wisconsin Company Buys Biomatrica

Biomatrica — started in 2005 by husband-and-wife scientists who invented a preservative for keeping DNA and other biological samples at room temperature — was acquired last month by Exact Sciences Corp.

Licensing Deal Gives Arena Cash for Pursuing Its Pipeline

Arena Pharmaceuticals on Nov. 15 announced a drug licensing deal that provides the company with ample cash to devote to other medicines in its pipeline.

Tease photo

Mirum Team Is on Familiar Ground With Liver Drug Effort

In 2014, pharmaceutical Shire bought San Diego company Lumena and its lead drug candidate, called maralixibat. Now maralixibat is back in the hands of former Lumena talent.

Tease photo

Grant Supports Salk Team’s Cutting-Edge Alzheimer’s Studies

A team of Salk Institute researchers has been awarded $19.2 million to study interactions among brain systems thought to underlie disorders like Alzheimer’s disease. Sparking new therapies is another goal.

Tease photo

Biotech Coworking Site Is Taking Applications

High demand for biotech startup space convinced BioLabs San Diego to open a second facility in the UTC area of San Diego.

Tease photo

Dexcom to Pay Verily $250M in Stock Through Amended Deal

San Diego’s Dexcom will pay $250 million in stock to Verily – a subsidiary of Google parent company Alphabet – as part an amended deal.

DJO Global Acquired for $3.15 Billion

Change is blowing through DJO Global, after the medical device company announced plans this summer to relocate from San Diego to Texas. Then came news on Nov. 19 that DJO was acquired for $3.15 billion.

Cibus Files for $100M IPO

Cibus – a San Diego company that uses gene editing to select desirable plant traits – is seeking $100 million through an initial public offering.

Ehrich Named CMO of Expansion Therapeutics

Elliot Ehrich, previously with Alkermes Plc, is the new chief medical officer of San Diego biotech startup Expansion Therapeutics.

Arthritis Drug Is Big Test for Samumed

MEDICINE: Co. Following Own Path on Investors, Valuation

Samumed emerged two years ago with a mission of regenerating hair, skin and joints, valued at a head-turning $12 billion.

Tease photo

Report: Jobs Increase in Life Sciences Sector

Employment in the life sciences sector in San Diego County rose 15.4 percent year over year, according to a recent report.

Tease photo

Arena Nets $800M Upfront in Licensing Deal

Arena Pharmaceuticals on Nov. 15 announced a drug licensing deal that provides the company with ample cash to devote to other medicines in its pipeline.

OncoSec’s Korean Ties Draw Attention in U.S. and S. Korea

Japan sticks out as San Diego biotech’s most valuable international trading partner. Elsewhere in Asia, regional biotechs like Tocagen are gaining a foothold in China through partnerships with Chinese firms.

Tease photo

StemGenex’s Marketing, Manufacturing Draw FDA Warning

StemGenex Biologic Laboratories recently drew a warning letter from the U.S. Food and Drug Administration over manufacturing practices and the marketing of an unapproved stem cell therapy.

Synthorx Files for $100M IPO

With a pipeline that activates tumor-fighting immune cells, Synthorx looks to raise $100 million through an initial public offering.

Scientist.com to Open an Office in Japan

The San Diego-based company recently experienced growth in its Japanese clientele, which includes several large pharmaceuticals.

Tease photo

Heron Therapeutics Reports Quarterly Results

San Diego-based Heron Therapeutics recently reported a quarterly loss of $38.3 million, or 49 cents per share.

Local Biotechs Battle Superbugs, While Facing Business Challenges

HEALTH: Region Has Talent, Grants, And Track Record for Fight

In a race to combat antibiotic resistance, big pharma bailed. Investors are skeptical. But Forge Therapeutics isn’t deterred.

Tease photo

Life Sciences Show That It’s Never Too Early to Be Heard

GOVERNMENT: From Reimbursement to Education, Efforts Made

Samumed has yet to put a drug on the market, but the company wants the ear of osteoarthritis policymakers and advocacy groups.

Tease photo

Mirum Pharmaceuticals Launches with $120M Round

San Diego-based Mirum Pharmaceuticals surfaced Nov. 7 with a $120 million Series A round – and plans to take a liver drug candidate into final-stage clinical trials.

Dexcom Revenue Rises 44 Percent in Q3

Dexcom’s revenue and net income shot up in quarter three results after the successful launch of its G6 diabetes monitoring system.

Q3: Neurocrine Reports Rising Drug Sales

San Diego biotech Neurocrine reported $151.8 million in quarter three revenue, a 150 percent year-over-year increase.

MEI Pharma Receives $10M Up Front in Licensing Deal

San Diego-based MEI Pharma licensed its drug candidate to Japanese company Kyowa Hakko Kirin, receiving $10 million up front, with an additional $87.5 million in development milestones and sales royalties possible if the drug wins approval in Japan.

Fiscal Policy Now On Front Burner at Scripps

HEALTH: Aim Is to Rely Less on NIH and More on Its Programs

Scripps Research’s latest annual statement shows a higher operating deficit than years past, but management predicted stronger financials amid a shift in direction.

Tease photo

ResMed to Buy MatrixCare for $750M

Medical device company ResMed looks to expand its software-as-a-service business through a recently announced acquisition.

Illumina Aims to Increase Sequencing Dominance with $1.2B Planned Acquisition

Illumina is poised to acquire niche competitor Pacific Biosciences for $1.2 billion, a deal analysts say would fortify Illumina’s dominance in genomic sequencing.

Halozyme Licenses Drug Delivery Technology to Roche

Halozyme Therapeutics is expanding the reach of its platform that delivers drugs under the skin, intended to do away with lengthy infusions.

Tease photo

Illumina to Buy Pacific Biosciences for $1.2 Billion

Illumina is poised to acquire Pacific Biosciences for $1.2 billion, a deal Illumina says will pave the way for a more complete view of the genome.